What factors are contributing to the unexpected 30% increase in manufacturing costs for Amgen's Repatha in the last six months?

Introduction

The unexpected 30% increase in manufacturing costs for Amgen's Repatha over the last six months presents a complex challenge that requires a systematic approach to uncover the root cause. As we delve into this issue, we'll examine various factors that could be contributing to this significant cost escalation, considering both internal and external influences on the manufacturing process.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might have been recent changes in the manufacturing process. Have there been any significant alterations to the production line or raw material sourcing in the past six months?

Why it matters: Changes in manufacturing processes can directly impact costs. Expected answer: Yes, there have been some modifications to improve efficiency. Impact on approach: If confirmed, we'd focus on analyzing the impact of these changes.

• Considering the scale of the increase, I'm wondering about external factors. Has there been any disruption in the supply chain or significant price changes for key ingredients?

Why it matters: External supply issues could explain sudden cost increases. Expected answer: There have been some challenges with certain suppliers. Impact on approach: This would lead us to investigate supply chain resilience and alternative sourcing options.

• Given that Repatha is a biologic drug, I'm curious about any changes in regulatory requirements. Have there been any new compliance measures implemented recently that might affect manufacturing costs?

Why it matters: Regulatory changes can significantly impact production costs in the pharmaceutical industry. Expected answer: No major regulatory changes have been implemented recently. Impact on approach: If confirmed, we'd shift focus to internal factors rather than regulatory compliance costs.

• Thinking about the manufacturing process itself, I'm wondering about production yield. Has there been any noticeable change in the yield or quality of Repatha produced over the last six months?

Why it matters: Changes in yield can directly affect per-unit manufacturing costs. Expected answer: There has been a slight decrease in yield, but not proportional to the cost increase. Impact on approach: This would prompt a deeper investigation into the factors affecting production efficiency.